Emergent BioSolutions Reports Financial Results for Second Quarter 2023
08 août 2023 16h31 HE
|
Emergent BioSolutions
Reports Q2 2023 total revenues of $338M, above the prior guidance range, net loss of $261M and adjusted EBITDA of $56MUpdates FY 2023 guidance and provides initial Q3 2023 forecast for total revenues ...
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
08 août 2023 07h15 HE
|
Emergent BioSolutions
Actions bring sharpened focus on MCM and NARCAN® Nasal Spray products Expected to improve operational efficiencies and deliver annual cost savings over $100 million annually GAITHERSBURG, Md.,...
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
31 juil. 2023 16h05 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., July 31, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that it was awarded a 10-year contract by the Biomedical Advanced Research and Development...
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
25 juil. 2023 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., July 25, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, August 8, 2023, at 5:00 pm eastern time to discuss the financial...
Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
20 juil. 2023 18h03 HE
|
Emergent BioSolutions
Emergent has been delivering CYFENDUS™ vaccine to the U.S. Department of Health and Human Services since 2019, under pre-Emergency Use Authorization status, and will continue to work with the U.S....
Emergent BioSolutions Announces CEO Transition
27 juin 2023 07h55 HE
|
Emergent BioSolutions
Robert G. Kramer Sr. to Retire Haywood Miller to Serve as Interim CEO GAITHERSBURG, Md., June 27, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS, “Emergent” or the “Company”) today...
Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
15 mai 2023 07h58 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., May 15, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions (NYSE: EBS) today announced it has completed the sale of its travel health business to Bavarian Nordic (OMX: BAVA). At...
Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
11 mai 2023 06h30 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., May 11, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) announced today that its 2023 Annual Meeting of Stockholders will be held in a virtual-only format via live...
Emergent BioSolutions Reports Financial Results For First Quarter 2023
09 mai 2023 16h05 HE
|
Emergent BioSolutions
Reports Q1 2023 total revenues of $165M, above the prior guidance range, net loss of $183M and adjusted EBITDA of negative $101MUpdates FY 2023 guidance and provides initial Q2 2023 guidance ...
Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
19 avr. 2023 16h05 HE
|
Emergent BioSolutions
GAITHERSBURG, Md., April 19, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Tuesday, May 9, 2023, at 5:00 pm eastern time to discuss the financial...